Clinical Trials
57 trialsNCT01013649 2026-02-23
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00640978 2025-05-01
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT02273362 2024-03-26
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01180959 2022-11-07
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02961374 2022-07-26
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00393068 2022-03-02
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00617708 2022-02-08
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT00591123 2021-10-01
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Phase 2 Completed
NCT01683422 2021-08-10
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
Loma Linda University
Phase NA Terminated
NCT00376948 2021-03-01
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00769483 2020-09-03
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01222689 2020-07-31
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00313560 2020-06-04
ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00539617 2020-03-23
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
University of California, San Francisco
Phase 2 Terminated
NCT00733746 2019-10-21
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00901901 2019-05-30
SEARCH
Bayer
Phase 3 Completed
NCT00940316 2019-05-07
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Northwestern University
Phase 2 Completed
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT01782690 2018-07-23
An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hoffmann-La Roche
Completed
NCT00832637 2018-06-29
Gem-ox
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00365144 2018-01-19
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
University of California, San Francisco
Phase 2 Completed
NCT00810719 2018-01-10
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
University of California, Davis
Phase 2 Completed
NCT00881751 2017-09-11
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Medical University of South Carolina
Phase 2 Completed
NCT00841035 2017-05-19
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
University of Alabama at Birmingham
Phase 2 Terminated
NCT00366457 2017-05-15
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00307736 2017-05-10
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Massachusetts General Hospital
Phase 1/2 Completed
NCT00550836 2017-04-05
Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02694536 2017-03-24
A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00761345 2017-03-07
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
Fox Chase Cancer Center
Phase 1 Completed
NCT01108458 2017-03-03
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Stanford University
Phase 2 Terminated
NCT00470535 2017-02-23
Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00336700 2016-09-19
A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT00696696 2016-06-30
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
NYU Langone Health
Phase 2 Completed
NCT00674973 2016-06-17
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01187901 2016-06-17
FAPEST
University of Utah
Phase 2 Completed
NCT00766636 2016-05-19
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00524121 2016-04-14
Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00532441 2016-02-12
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00461708 2015-10-15
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
Hoffmann-La Roche
Phase 2 Completed
NCT00925769 2015-08-07
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT00442507 2015-07-24
OSI3650
Washington University School of Medicine
Phase 2 Terminated
NCT00365391 2015-07-09
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01093222 2015-06-30
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00735306 2015-06-18
TART
Duke University
Phase 1 Completed
NCT00652366 2015-02-11
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01135498 2015-02-06
A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00754494 2015-01-06
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00482625 2014-10-16
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated